Tekmira has demonstrated multi-gene knockdown using MV-RNA enabled by proprietary LNP formulations.
Under the collaboration, both the companies will work together to develop and design MV-RNA molecules to gene targets of interest to Tekmira and to combine MV-RNA molecules with Tekmira’s lipid nanoparticle (LNP) technology to develop therapeutic products.
Tekmira president and CEO Mark Murray said their exclusive license to Halo-Bio’s MV-RNA technology expands and diversifies their technology base to support the development of novel products and gives us the opportunity for broader discussions with the pharmaceutical industry.
"We believe we can accelerate the development of the MV-RNA technology by leveraging our know-how and expertise in LNP delivery as well as our understanding of therapeutic RNA payload design," Murray said.